Undisclosed VLP vaccine / Allergy Therap, Saiba Biotech - LARVOL DELTA

Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals. (PubMed, J Allergy Clin Immunol) - P1 | "VLP Peanut displayed tolerogenic properties by modulating DCs, T cells, and B cells in vitro. Preliminary findings of skin reactivity using VLP Peanut in 6 peanut-allergic adults was safe and well tolerated in an open-label phase 1 study."

Journal • Preclinical • Allergy • Food Hypersensitivity • Immune Modulation • Immunology • IFNG • IL10 • IL4 • MX1

Hypoallergenic Safety Profile of a Novel Virus-like Particle Vaccine for the Treatment of Peanut Allergy supported by Skin Prick Testing (AAAAI 2024) - "The SPT results of the PROTECT study further support the hypo-allergic action of VLP Peanut in peanut allergic patients. These data strongly support to progress to the multiple subcutaneous dose escalation in both healthy subjects (Phase I) and peanut allergic patients (Phase IIa) of the PROTECT study."

Clinical • Allergy • Food Hypersensitivity • Immunology

Influence of antigen density and TLR ligands on preclinical efficacy of a VLP-based vaccine against peanut allergy. (PubMed, Allergy) - "Our findings demonstrate that prokaryotic RNA encapsulated within VLP Peanut, including antigen density of Ara h 2 on viral particles, are key contributors to the immunogenicity and protective capacity of the vaccine. Thus, antigenicity and RNA content are two critical quality attributes that need to be determined at the stage of manufacturing, providing robust information regarding the immunogenicity and protective capacity of VLP Peanut in the mouse which has translational relevance to the human setting."

IO biomarker • Journal • Preclinical • Allergy • Food Hypersensitivity • Immunology • TLR3

The next generation virus-like particle platform for the treatment of peanut allergy. (PubMed, Allergy) - "VLP Peanut can be delivered to peanut-sensitized mice without triggering allergic reactions, whilst remaining highly immunogenic and offering protection against all peanut allergens. In addition, vaccination ablates allergic symptoms upon allergen challenge. Moreover, the prophylactic immunization setting conferred the protection against subsequent peanut-induced anaphylaxis, showing the potential for preventive vaccination. This highlights the effectiveness of VLP Peanut as a prospective break-through immunotherapy vaccine candidate towards peanut allergy. VLP Peanut has now entered clinical development with the study PROTECT."

Journal • Allergy • Food Hypersensitivity • Immunology

In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma. (PubMed, J Immunother Cancer) - "Our new immune-enhancer turned immunologically cold tumors into hot ones and inhibited local and distant tumor growth. This type of immunotherapy does not require the identification of (patient-individual) relevant tumor antigens. It is well tolerated, non-infectious, and affordable, and can readily be upscaled for future clinical testing and broad application in melanoma and likely other solid tumors."

Journal • Preclinical • Immunology • Infectious Disease • Inflammation • Melanoma • Oncology • Solid Tumor • Tetanus • CD4 • CD8

Virus-like particle vaccinology, from bench to bedside. (PubMed, Cell Mol Immunol) - "Here, we focus on the use of VLPs for the development of vaccines with broad fields of indications ranging from classical vaccines against viruses to therapeutic vaccines against chronic inflammation, pain, allergy and cancer. In this review, we take a walk through time, starting with the latest developments in experimental preclinical VLP-based vaccines and ending with marketed vaccines, which earn billions of dollars every year, paving the way for the next wave of prophylactic and therapeutic vaccines already visible on the horizon."

Journal • Review • Allergy • Immunology • Inflammation • Oncology • Pain

A novel virus-like particle for the treatment of cat allergy (BSACI 2022) - "Both vaccines were nonreactogenic against systemic challenge with the allergen. The specific induction of IgG antibodies for Fel d1 was robust and sustained, these results suggest a therapeutic advantage for a Fel d1 vaccine against cat allergy and highlight a novel approach in the design and application of VLPs genetically fused with an antigen target."

Allergy • Immunology • Infectious Disease • Tetanus

Vaccination against peanut allergy – a paradigm shift? (BSACI 2022) - "Proof of concept of a novel vaccine against peanut allergy based on engineered virus-like particles (CuMV-Ara h 2; VLP Peanut) has been established, providing unique mechanistic and translational insights for a first-in-human study in 2022...This is striking and could be applied in different allergies, caused by sensitisation against more than one allergen. First inhuman trials are now planned."

Allergic Rhinitis • Allergy • Food Hypersensitivity • Immunology